Studies focusing on the HR- and mismatch repair pathways in relation to 17AAG + cisplatin response in DLBCL are warranted to decipher the role of DNA repair and Hsp90 inhibitors in cisplatin and other DNA damaging drug responses in DLBCL. This evidence concerns the gene HSP90AB1 and diffuse large B-cell lymphoma.